By King & Wood Mallesons

On February 20, 2018, Yunfeng Fund signed the agreement with MicroPort Scientific Corporation (“MicroPort”, HK:853), a medical company listed in Hong Kong, jointly acquiring cardiac rhythm management business (CRM business) of LivaNova PLC in the United Kingdom by funding MicroPort Cardiac Rhythm B.V. (“MicroPort Cardiac”). The business mainly includes R&D, manufacture and sale of pacemakers, defibrillators and cardiac resynchronization devices with the purchase price of 190 million U.S. dollars. Upon completion of the acquisition, Yunfeng Fund will indirectly hold 25% of the CRM business through MicroPort Cardiac.
Continue Reading King & Wood Mallesons advises Yunfeng Fund and MicroPort jointly acquired LivaNova PLC’s cardiac rhythm management business ranking fifth largest in the world